SaaS entity
All 1 tracked stories fall under one category: earnings. Mineralys Therapeutics is most often covered alongside CareCloud, which appears in 1 of these 1 story. Source depth averages 15 original sources per story, versus 3.4 across the same-window beat baseline.
Last mentioned: Mar 13, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. Mineralys Therapeutics is most often covered alongside CareCloud, which appears in 1 of these 1 story. Source depth averages 15 original sources per story, versus 3.4 across the same-window beat baseline. Their average consequence score of 7 runs above the beat's 6.4 for that window. Mineralys Therapeutics appears in 1 tracked SaaS story from March 13, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 SaaS stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Mineralys Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
CareCloud achieved its first profitable year since its 2014 IPO, driven by its AI Center of Excellence and strategic acquisitions. Meanwhile, HeartBeam and Vuzix are pivoting toward high-margin software and engineering services, signaling a broader trend of hardware-to-SaaS transitions.
Mineralys Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
